Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons (vol 9, pg 1491, 2018)

被引：1
|
作者：
Balijepalli, Chakrapani [1 ]
Shirali, Rohan [1 ]
Kandaswamy, Prashanth [2 ]
Ustyugova, Anastasia [2 ]
Pfarr, Egon [2 ]
Lund, Soren S. [2 ]
Druyts, Eric [1 ]
机构：
[1] Precis Hlth Econ, Vancouver, BC, Canada
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
DIABETES THERAPY | 2019年 / 10卷 / 01期
关键词：
D O I：
10.1007/s13300-018-0543-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The authors have updated Fig. 3 which was incorrectly published in the original publication.
引用
收藏
页码：325 / 326
页数：2
相关论文
共 50 条
  • [31] Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate is Not yet Closed
    Guillausseau, Pierre-Jean
    CURRENT DIABETES REPORTS, 2011, 11 (06) : 461 - 462
  • [32] Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate is Not yet Closed
    Pierre-Jean Guillausseau
    Current Diabetes Reports, 2011, 11 : 461 - 462
  • [33] Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review
    Samoilova, Iuliia G.
    Vaizova, Olga E.
    Stankova, Anastasia E.
    Matveeva, Mariia, V
    Podchinenova, Daria, V
    Kudlay, Dmitry A.
    Borozinets, Anastasiia A.
    Filippova, Tatyana A.
    Grishkevich, Ivan R.
    Partala, Anastasia, V
    Gerasimova, Diana A.
    TERAPEVTICHESKII ARKHIV, 2024, 96 (01) : 63 - 67
  • [34] Regional variation of prescribing Dipeptidyl peptidase-4 (DPP-4) inhibitors to patients with Type 2 diabetes with renal impairment: The UK general practice experience
    Spanopoulos, D.
    Barrett, B.
    Busse, M.
    Roman, T.
    Poole, C.
    DIABETIC MEDICINE, 2018, 35 : 62 - 62
  • [35] Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes
    Brigance, Robert P.
    Meng, Wei
    Fura, Aberra
    Harrity, Thomas
    Wang, Aiying
    Zahler, Robert
    Kirby, Mark S.
    Hamann, Lawrence G.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (15) : 4395 - 4398
  • [36] Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy
    Yen, Fu-Shun
    Chiang, Jen-Huai
    Pan, Chun-Wei
    Lin, Boniface J.
    Wei, James Cheng-Chung
    Hsu, Chih-Cheng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 140 : 279 - 287
  • [37] Dipeptidyl Peptidase-4 Inhibitors Do Not Increase the Risk of Cardiovascular Events in Type 2 Diabetes
    Kim, Seoyoung C.
    Glynn, Robert
    Liu, Jun
    Everett, Brendan
    Goldfine, Allison
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 188 - 189
  • [38] Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus
    Davidson, Michael H.
    POSTGRADUATE MEDICINE, 2014, 126 (03) : 56 - 65
  • [39] The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
    Yousefzadeh, Pegah
    Wang, Xiangbing
    JOURNAL OF DIABETES RESEARCH, 2013, 2013
  • [40] The safety of dipeptidyl peptidase-4 ( DPP-4) inhibitors or sodium- glucose cotransporter 2 ( SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta- analysis
    Kawalec, Pawel
    Mikrut, Alicja
    Lopuch, Sylwia
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (04) : 269 - 283
12345